NBCA/X
May 8, 2026, 06:03
Risk-Stratified HRT Use Following VTE – NBCA
NBCA shared a post on X:
“The blanket ‘no HRT after VTE’ approach is being challenged — and Dr. Cromwell is leading that conversation.
Her focus: which patient, which formulation, which risk level.
Route matters — transdermal > oral.
Thrombophilia and provocation status are critical.
Progestogen choice matters.
Hematology plus gynecology must collaborate.
Join Dr. Cromwell at NBCA’s May PEP Talk: Women and Blood Clots.
May 12 | 7 PM ET.”
Stay updated with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers